Methodological guidelines for rapid relative effectiveness assessment (REA) of Pharmaceuticals
1. Clinical endpoints
2. Composite endpoints
3. Surrogate endpoints
4. Safety
5. Health-related quality of life
6. Criteria for the choice of the most appropriate comparator(s)
7. Direct and indirect comparison
8. Internal validity
9. Applicability of evidence in the context of a relative effectiveness assessment
Please note that the updated versions of these Guidelines can be found under JA2 Guidelines here.